PHARMACOKINETICS (PK) OF PROPYLENE GLYCOL-FREE MELPHALAN HCL (PG-FREE MEL) IN MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION (AHCT)

被引：0
|
作者：
Hari, P. [1 ]
Dhakal, B. [1 ]
D'souza, A. [1 ]
Thompson, R. [1 ]
Hamadani, M. [1 ]
Pasquini, M. [1 ]
Chhabra, S. [1 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1523
引用
收藏
页码：621 / 621
页数：1
相关论文
共 50 条
  • [41] Full Dose or Reduced Dose Melphalan (MEL) for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): A Single Center Analysis on 187 Consecutive Patients
    Brioli, Annamaria
    Felix, vom Hofe
    Muegge, Lars-Olof
    Scholl, Sebastian
    Hilgendorf, Inken
    Sayer, Herbert G.
    Yomade, Olaposi
    Ernst, Thomas
    Hochhaus, Andreas
    von Lilienfeld-Toal, Marie
    BLOOD, 2018, 132
  • [42] A Phase 3 Study Comparing Melphalan-Prednisone-Lenalidomide (MPR) With High-dose Melphalan and Autologous Transplantation (MEL200) in Newly Diagnosed Patients With Multiple Myeloma (MM)
    Palumbo, A.
    Cavallo, F.
    Di Raimondo, F.
    di Toritto, T. Caravita
    Grammatico, S.
    Corradini, P.
    Omede, P.
    Ben Yehuda, D.
    Nagler, A.
    Boccadoro, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S639 - S639
  • [43] Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients
    Boccadoro, Mario
    Cavallo, Federica
    Gay, Francesca Maria
    Di Raimondo, Francesco
    Nagler, Arnon
    Montefusco, Vittorio
    Patriarca, Francesca
    Tacchetti, Paola
    Guglielmelli, Tommasina
    Musto, Pellegrino
    Baldini, Luca
    Crippa, Claudia
    Ruggeri, Marina
    Gentilini, Fabiana
    Cavalli, Maide
    Ben Yehuda, Dina
    Caravita, Tommaso
    Ciccone, Giovannino
    Hardan, Izhar
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Risk factors for oral mucositis (OM) in multiple myeloma (MM) patients receiving high-dose melphalan (Mel) prior to autologous stem cell transplantation (SCT).
    Bhatnagar, Bhavana
    Goloubeva, Olga G.
    Gilmore, Steven
    Hoffman, Arnold
    Ruehle, Kathleen
    Akpek, Gorgun
    Rapoport, Aaron
    Yanovich, Saul
    Badros, Ashraf Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [45] The conventional body surface area (BSA) method of calculating the dose of melphalan (MEL) results in widely variable MEL exposure and mucositis risk in myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT).
    Anaissie, EJ
    Grazziutti, ML
    Li, D
    Miceli, MH
    Fassas, A
    Thertulien, R
    Rajan, S
    Saghafifar, F
    Tricot, GJ
    Barlogie, B
    BLOOD, 2004, 104 (11) : 328A - 328A
  • [46] High Dose Intravenous Busulfan (BU) and Melphalan (MEL) Followed by Bortezomib (BTZ) as Conditioning with Autologous Peripheral Blood Stem Cell Transplantation (ASCT) for Patients with Multiple Myeloma (MM)
    Rodriguez, Tulio E.
    Stiff, Patrick J.
    Smith, Scott E.
    Kaufman, Jonathan L.
    Lee, Mary
    Parthasarathy, Mala
    Earley, Zachary M.
    Lonial, Sagar
    Vesole, David H.
    BLOOD, 2010, 116 (21) : 582 - 582
  • [47] Toxicity and early response after intravenous (IV) busulfan (Bu) plus melphalan (Mel) conditioning for autologous stem cell transplantation (SCT) in patients (pts) with multiple myeloma (MM).
    Kebriaei, Partow
    Giralt, Sergio
    Madden, Timothy L.
    Thapar, Neil
    Shpall, Elizabeth J.
    Hosing, Chitra
    Qazilbash, Muzaffar H.
    Couriel, Daniel R.
    Popat, Uday
    Thall, Peter F.
    Champlin, Richard E.
    Jones, Roy
    Andersson, Borje S.
    BLOOD, 2006, 108 (11) : 833A - 833A
  • [48] Pharmacokinetics and Toxicities after Evomela (Propylene Glycol Free Melphalan) with Hematopoietic Stem Cell Transplant (HCT) for Multiple Myeloma (MM), AL Amyloidosis (AL), Lymphoma, Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS)
    Shah, Gunjan L.
    Landau, Heather
    Sarubbi, Caitlin
    Schofield, Ryan
    Lin, Andrew
    Bhatt, Valkal
    Harnicar, Stephen
    Devlin, Sean M.
    Castro-Malaspina, Hugo
    Chung, David J.
    Dahi, Parastoo B.
    Gyurkocza, Boglarka
    Koehne, Guenther
    Matasar, Matthew J.
    Moskowitz, Craig H.
    Papadopoulos, Esperanza B.
    Sauter, Craig S.
    Shaffer, Brian C.
    Tamari, Roni
    Carlow, Dean
    Giralt, Sergio A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S79 - S80
  • [49] Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
    Ozkurt, Zuebeyde Nur
    Sucak, Gulsan Tuerkoez
    Aki, Sahika Zeynep
    Yagci, Munci
    Haznedar, Rauf
    CANCER INVESTIGATION, 2017, 35 (03) : 195 - 201
  • [50] Phase I dose escalation of intravenous busulfan (Bu) with a fixed dose of melphalan (Mel) in patients (pts) with multiple myeloma (MM) undergoing autologous peripheral blood stem cell transplant (PBSCT).
    Callander, NS
    Cortes, R
    Freytes, CO
    Gokmen, E
    Ochoa, L
    Tran, HT
    Nguyen, J
    Roodman, GD
    BLOOD, 2001, 98 (11) : 201A - 201A
12345